Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples

• Egile Nagusiak: James P. Solomon (Egilea), Carlos Munoz-Zuluaga (Egilea), Cheyanne Slocum (Egilea), Alicia Dillard (Egilea), Lin Cong (Egilea), Jiajing Wang (Egilea), Neal Lindeman (Egilea), Michael Kluk (Egilea), Benjamin Liechty (Egilea), David Pisapia (Egilea), Hanna Rennert (Egilea), Priya D. Velu (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract IDH1 and IDH2 mutational status is a critical biomarker with diagnostic, prognostic, and treatment implications in glioma. Although IDH1 p.R132H-specific immunohistochemistry is available, it is unable to identify other mutations in IDH1/2. Next-generation sequencing can accurately determin...